Needham raised the firm’s price target on Taysha Gene Therapies (TSHA) to $8 from $6 and keeps a Buy rating on the shares after Taysha last week reported updated clinical data from the adult/pediatric REVEAL studies and details on an FDA-aligned pivotal study. Evidence of dose-dependence is further de-risking for TSHA-102 and the firm views this update as “a win across the board,” the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Positive Outlook for Taysha Gene Therapies: Buy Rating on Promising TSHA-102 Advancements
- Positive Outlook for Taysha Gene Therapies: Strong Study Design and Promising Data Support Buy Rating
- Taysha Gene Therapies Announces Major Stock Offering
- Taysha Gene Therapies price target raised to $9 from $7 at Chardan
- Taysha Gene Therapies 46.9M share Spot Secondary priced at $2.75